Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
University of Pittsburgh
M.D. Anderson Cancer Center
Exelixis
Neonc Technologies, Inc.
Dana-Farber Cancer Institute
University of Pittsburgh
University of Pittsburgh
Incyte Corporation
Emory University
Iovance Biotherapeutics, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Providence Health & Services
Xencor, Inc.
National Cancer Institute (NCI)
AIO-Studien-gGmbH
Incyte Corporation
Incyte Corporation
Threshold Pharmaceuticals